

THE

# CANCER LETTER

P.O. BOX 2370 RESTON, VIRGINIA TELEPHONE 703-620-4646

Vol. 5 No. 37

Sept. 14, 1979

© Copyright 1979  
The Cancer Letter Inc.  
Subscription \$125.00 per year

## CARCINOGENESIS TESTING MOVED OUT OF DCCP TO NEW STATUS AS DIVISION, GIVING RALL MORE AUTHORITY

The Carcinogenesis Testing Program has been removed from the Div. of Cancer Cause & Prevention by NCI Director Arthur Upton, and, in effect, established as a new division within NCI to "assure clear lines of responsibility and authority" in CTP's relationship with the National Toxicology Program.

The move by Upton was designed to alleviate the situation in which  
(Continued to page 2)

### In Brief

#### PANEL APPOINTMENTS ON PRESIDENT'S DESK; BREAST CANCER TREATMENT WORKSHOP PLANNED

**PRESIDENT CARTER** has the two appointments to fill vacancies on the Cancer Panel on his desk, and they may be announced momentarily. Anticipating that the appointments will be made soon, NCI has scheduled a meeting of the Panel for Oct. 15, 2-5 p.m., Bldg 31 Room 11A10. . . . **WILLIAM SHINGLETON**, director of the Duke Comprehensive Cancer Center, has been awarded an endowed professorship, the Edwin L. Jones Jr. and Lucille Finch Jones Cancer Research Chair. Shingleton is a member of the National Cancer Advisory Board and is professor of surgery and chief of the general surgery division at Duke. . . . **NEW RESEARCH** strategies to develop more effective treatment for breast cancer will be subject of a three day workshop starting Oct. 29 in Detroit, sponsored by Comprehensive Cancer Center of Metropolitan Detroit, NCI and the American Cancer Society. The organizing committee is headed by Marvin Rieh, executive director of the Michigan Cancer Foundation and includes Louis Sibal, special assistant to the director of NCI's Div. of Cancer Cause & Prevention; and Frank Rauscher, ACS senior vice president for research. Charles McGrath, chairman of the Michigan Cancer Foundation tumor biology department, is meeting chairman. . . . **CORRECTION:** *The Cancer Letter* listed in the Aug. 31 issue the 1st International Congress on Ultrasonic Examination of the Breast as scheduled for Oct. 8-9 in Australia. The meeting will be held on those days in Philadelphia, at the Franklin Hotel. . . . **SUMMARY REPORT** on the NIH grants peer review study is available from the Office of Grants Inquiries, Div. of Research Grants, NIH, Westwood Bldg Rm 448, Bethesda, Md. 20205. . . . **NATIONAL CANCER** Advisory Board subcommittee meetings in conjunction with the Board's Oct. 3-5 session have been scheduled: Organ Site, Oct. 2, closed; Centers, Oct. 2, 1 p.m.—adjournment, Bldg 31 Room 6, open; Centers, Oct. 3, 7:30 p.m., closed; Special Actions, Oct. 3, closed; and Environmental Carcinogenesis, Oct. 3, 7:30 p.m., Bldg 31 Room 7A24, open. The full Board meetings Oct. 3, 1 p.m.—adjournment, and Oct. 5, 9 a.m.—1 p.m., will be open; the Tuesday meeting will be closed all day for grant review.

Upton Finds Work  
For Former Division,  
Program Directors  
. . . Page 3

NCI Staff Phone  
Numbers Listed  
. . . Page 4

RFPs Available,  
Sources Sought  
. . . Page 8

Contract Awards  
. . . Page 7

## UPTON SPLITS DEPUTY TASKS AMONG HIS STAFF, WILL NOT REPLACE GUY NEWELL

(Continued from page 1)

NTP Director David Rall felt he did not have sufficient authority over CTP and its staff (*The Cancer Letter*, Sept. 7). Upton said in a memo to CTP Director Richard Griesemer announcing the change that Rall should be considered the de facto "division director" of CTP.

In another development, Upton assigned to various members of his staff the duties which had been performed by Deputy Director Guy Newell, who left Sept. 1 for his new job at M.D. Anderson. Upton is not looking for a replacement for Newell, which indicates either (1) he is leaning closer to a decision to leave NCI himself in the near future and feels it would not be appropriate to hire a new deputy, or (2) with the hiring freeze which will extend at least through the end of the month, he couldn't hire anyone even if he wanted to.

Upton's memo to Griesemer:

"On July 13, the director of NIH directed that you and your staff be 'detailed' by the National Cancer Institute to the National Toxicology Program, rather than to the director of the Div. of Cancer Cause & Prevention. I am also directing my staff that henceforth documents committing resources allocated by NCI to NTP should be accepted with your signature as program director and Dr. Rall's signature (or his designated deputy director, Dr. Moore) as division director. This will effectively place your program organizationally under the OD/NCI, rather than under DCCP, for the duration of the present NTP experiment.

"In addition, I am directing my staff to forward any questions or requests for data concerning the Carcinogenesis Testing Program directly to you for response. They will expect you to coordinate such responses with your NTP superiors and that any responses you supply will reflect the NTP position.

"We are prepared to allocate resources to NTP—notably positions and dollars—subject to strictures over which NCI has no control. These resources will be available exclusively for NTP activities and will be delineated in memoranda of understanding between NCI and NTP. These sub-allocations will be reported to NIH.

"Unless alternative arrangements are made, administrative and other supporting efforts of NCI units that support CTP activities will continue as before. I have directed my staff to provide the utmost cooperation in this effort, and I expect them to do so. I am asking each appropriate support group (e.g., Personnel Management Branch, Research Contracts Branch) to designate staff whose principal responsibility is to work with and support the CTP. In addition, the administrative officer, CTP, will report to you, with functional oversight by Mr. Robert Namovicz [NCI

deputy executive officer], rather than by the administrative officer, DCCP. In each instance, attention of these staff members will be directed toward your priorities. If you think that problems are emerging in this regard, please contact Mr. Namovicz, who is serving as the NCI coordinator for this effort.

"I trust this arrangement will resolve some of the uncertainty surrounding CTP's relationship with NTP and will establish clear and unambiguous channels of communication, authority and responsibility, thereby simplifying administration and placing full responsibility for your program with the director, NTP. Our intent is to facilitate the NTP and to enhance its ability to achieve its goals."

**It is possible that the Carcinogenesis Testing Program's status as a division will preclude fulfillment of Upton's plan to establish a new prevention division.**

CTP would have been one of the major components considered for transfer to the new division. Apart from that, it does not seem likely that HEW would favor creating two new divisions, even if one of them were to be without formal designation as such.

The CTP de facto division could perhaps form the skeleton of a new division, with other programs added to it eventually. By using Rall as the division director, Upton gets around the freeze on positions. Rall already has two other jobs—director of the National Institute of Environmental Health Sciences and NTP director, a unique situation in itself. He is probably the only person in NIH history to simultaneously be a division director in one institute and director of another.

Upton this week was reportedly close to wrapping up reorganization of the Div. of Cancer Control & Rehabilitation, which in his original projection would take in the centers, construction, organ site and training programs. If a prevention division is formed, the reorganized DCCR probably would lose its Preventive Medicine Branch to the new division.

Meanwhile, Upton split up the jobs Newell had been doing among the associate and assistant directors on his staff. Here is his memo on that subject:

"With Dr. Newell's departure, I have assigned certain of his former responsibilities on an interim basis as indicated below.

"A. Coordination of Diet-Nutrition Program activities are assigned to Dr. Diane Fink. Dr. Fink will act as the project officer on all contracts for which this role was previously filled by either Dr. Newell or Dr. [Mildred] Ellison. As in the past, Dr. Donald Luecke will perform the duties of program director on diet-nutrition grants and coordinate performance of these duties with Dr. Fink as he did with Dr. Newell.

"B. Oversight and general supervision of the Office of Research Safety as previously performed by

Dr. Newell will be performed by Dr. John Moloney. Dr. [Emmett] Barkley's responsibilities will not be otherwise affected. [Barkley is director of that office.]

"C. Management and project officer responsibilities over the New Jersey Coordinating Contract will be assumed by Dr. John Moloney. [See below.]

"D. All responsibilities for coordination or management of programs, contracts, or activities related to the secretary's initiative on low-level radiation formerly performed by Dr. Newell will be assumed by Dr. Oddvar Nygaard on his arrival. In the interim, Mr. [Louis] Carrese will assume Dr. Newell's functions. Dr. Elliott Stonehill and Dr. Victor Zeve will continue their activities in this program but will relate initially to Mr. Carrese, and then to Dr. Nygaard.

"E. Oversight and general supervision of the staff of the Journal of the National Cancer Institute as previously performed by Dr. Newell will be performed by Dr. Bayard Morrison. This does not affect Dr. [John] Bailar's responsibilities except as to reporting relationship.

"E. During my absences from the office Dr. Bayard Morrison will be acting NCI director.

"G. All other functions performed by Dr. Newell as deputy director will be addressed on an ad hoc basis by appropriate staff in the office of the director. Documents requiring signature of the deputy director should be prepared without name identification, and with the title 'Acting Deputy Director,' until further notice."

In another and less controversial switch, the International Cancer Research Data Bank was moved out of the Office of International Affairs into the Div. of Cancer Cause & Prevention. Main reason for the change: DCCP Director Gregory O'Connor, who previously headed the Office of International Affairs and thus was closely involved with development of ICRDB, wanted to continue that involvement. John Schneider will continue as ICRDB director.

Upton appears to have found plenty of work for the associate and assistant directors he had moved into his office when he determined it was necessary to move them out of their previous positions.

Fink, former DCCR director, now has the title of associate director for medical applications of research. In addition to taking over direction of the Diet-Nutrition Program, she also has responsibility for the Smoking & Health Program and is heavily involved in the NIH consensus development conferences relating to cancer.

Moloney, long time and highly respected head of the Viral Oncology Program, has been assigned, as assistant director, responsibility for development of a long range plan for the Frederick Cancer Research Center; supervision of the task forces reviewing each of the major NCI program areas; counselor to super-grade employees in their dealings with the Senior

Executive Service and review of their requests for outside employment.

The New Jersey "coordinating contract" which Upton assigned to Moloney is with the state of New Jersey to develop a plan for cancer control activities. Award of this contract was "encouraged" by former HEW Secretary Joseph Califano, and Upton retained supervision of it in his office. The amount involved is \$356,000.

Marvin Schneiderman, former head of Field Studies & Statistics in DCCP, has the title now of associate director for science policy. Upton has assigned him the job of representing NCI in dealing with the regulatory agencies on development of their policies related to cancer prevention. He also advises Upton on other prevention activities.

Gio Gori, who at the moment still technically holds the position of deputy director of DCCP, also is listed as assistant director in Upton's office. He will be replaced soon in the DCCP position by Louis Sibal, who has been acting in that role for the past year while Gori was getting his master of public health degree at Johns Hopkins Univ.

Gori's responsibilities will include coordination of toxicology and research on chemical components of tobacco in the Smoking & Health Program; advisor to Upton on the science of prevention; executive secretary of the interagency Heart, Lung & Cancer Group; chairman of the Health Effects Committee for Stratospheric Ozone Protection; NIH representative in other activities relating to the impact of ultraviolet radiation; and other ad hoc research assignments to be determined.

NCI executives earlier had indicated that Gori would return as head of the Smoking & Health Program, which he started in the early 1970s and had directed along with his other duties ever since, when he finished his Hopkins studies. However, those executives now say that the character of the program is changing from one emphasizing research to one in which the major effort will be application of research findings. Fink is more suited to directing that effort, they feel.

Morrison, as the designated director in Upton's absence, apparently is the closest to assuming the role of acting deputy director. He has been an assistant director for years, serving chiefly as the director's representative with various organizations, handling congressional correspondence, and advising on certain personnel matters. He has been NCI's chief activist in dealing with unproven treatment methods, particularly laetrole.

Richard Tjalma is another assistant director who, like Morrison, has held that position under several NCI directors. He is executive secretary of the President's Cancer Panel and represents Upton on matters involving Frederick Cancer Research Center.

Other associate directors reporting directly to Upton have roles clearly defined by their titles—Louis

Carrese, Program Planning & Analysis; Robert Miller, International Affairs; William Terry, Cancer Centers; Paul Van Nevel, Cancer Communications.

Calvin Baldwin, NCI executive officer for many years, holds what is perhaps the second most powerful position in the institute.

A number of changes in key staff positions throughout NCI have recently occurred or soon will, most of them involving promotions.

Probably the biggest promotion is going this week to Robert Goldberger, chief of the Laboratory of Biochemistry in the Div. of Cancer Biology & Diagnosis. He will take over the important and prestigious position of NIH deputy director for science, replacing Dewitt Stetten who will become senior scientific advisor.

Harold Simpson, who was chief of the Biology & Diagnosis Section in the Research Contracts Branch, has retired. Philip Webb is the new acting chief.

Stuart Bentley is acting chief of the Quantitative Cytology Section in DCBD's Laboratory of Pathology, replacing Chester Herman.

Michael Goldrich, who was administrative officer in the Div. of Cancer Treatment's Developmental Therapeutics Program, is the new administrative officer for the entire division. He replaces Philip Amoroso, who left to become executive officer of the National Library of Medicine.

Vincent Chairoli is the new director of the Large Bowel Program in the Organ Site Programs Branch.

Diane Wax, who handled legislative liaison duties in Baldwin's office, moved up to the Office of Program Planning & Evaluation in the Public Health Service headquarters as an analyst responsible for NIH programs. John Abbott has assumed Wax's NCI duties.

#### NCI STAFF LISTED WITH PHONE NUMBERS IN CURRENT ORGANIZATIONAL FRAMEWORK

The ink was hardly dry on the newest edition of the NIH phone directory before it was out of date, at least as far as NCI listings are concerned.

The directory editors also had to contend with the confusing situation in which the NCI reorganization has been partially put into effect but not officially cleared with HEW. Some programs and offices had to be listed with their old divisions, although they no longer are operating through them. As always, staff changes occurred after the directory went to press.

Finally, the directory is now printed directly from computer printouts with the hard to read electrostatic type. As a service to those who contact NCI staff members, and as a guide to those who are following the NCI reorganization, *The Cancer Letter* has compiled the following staff directory. The area code for most phone numbers is 301. For those offices not located in Maryland, the area code is listed.

The NIH directory includes the building and room numbers of each staff member listed. The listings below do not, due to space limits. Mail may be addressed to the individual, division, branch, laboratory, etc., National Cancer Institute, Bethesda, Md. 20205 (note the change in ZIP code, from the old 20014).

#### OFFICE OF THE DIRECTOR

Director—Arthur C. Upton	496-5615
Office of Administrative Management	
Executive Officer—Calvin B. Baldwin Jr.	496-5737
Deputy Executive Officer—Robert M. Namovicz	496-5737
Legislative Liaison—John Abbott (acting)	496-5217
Administrative Services Branch	
Chief—Tim L. Kearns	496-5801
Office Services Section Chief—L. Paul Wade	496-6002
Laboratory Services Section Chief—Don Ecker	496-4160
Financial Management Branch	
Chief—John Hartinger	496-5803
Budget Officer—Stephen A. Ficca	496-5803
Management Policy Branch	
Chief—Paul Schaffer (acting)	496-6985
Personnel Management Branch	
Chief—Elizabeth Stroud	496-3337
Research Contracts Branch	
Chief—James E. Graalman	496-3573
Biology & Diagnosis Contracts Section	
Chief—Philip Webb (acting)	496-5565
Control & Rehabilitation Contracts Section	
Chief—David M. Keefer	427-8747
Treatment Contracts Section	
Chief—George E. Summers Sr.	427-8737
Carcinogenesis Contracts Section	
Chief—Daniel J. Longen	427-8764
Viral Oncology & Field Studies Contract Section	
Chief—Charles Fafard	496-1781
Assoc. Dir. for Program Planning & Analysis	
Louis M. Carrese	496-6445
Assoc. Dir. for Medical Applications of Research—	
Dr. Diane J. Fink (acting)	496-1316
Assoc. Dir. for International Affairs; Director, Office of International Affairs—	
Dr. Robert Miller (acting)	496-4761
Deputy Director—Dr. Joseph F. Saunders	496-6343
Special Consultant—Dr. John R. Heller	496-6343
US-USSR Oncologic Research Activities	
Program Manager—Dr. Joseph F. Saunders	496-6343
NCI-Japan Cooperative Cancer Research Program	
Executive Secretary—Dr. Robert R. Omata	496-6343
Assoc. Dir. for Science Policy—	
Dr. Marvin A. Schneiderman (acting)	496-1611
Assoc. Dir. for Cancer Centers; Director, Cancer Centers Program—	
Dr. William D. Terry (acting)	496-7427
Cancer Centers Branch	
Chief—Dr. William L. Roberson	496-7424
Research Facilities Branch	
Chief—Dr. Donald Fox	496-7141
Assoc. Dir. for Cancer Communications; Director, Office of Cancer Communications—	
J. Paul Van Nevel	496-6631
Reports and Inquiries Branch	
Chief—William S. Gray	496-6641
Public Inquiries Section Chief—	
Robert J. Avery Jr.	496-5583
Reports Section Chief—	
Dr. Robert M. Hadsell	496-6641

Information Resources Branch			
Graphics and Audiovisuals Section Chief— Pauline Wall	496-4394		
Information Projects Branch			
Chief—Elaine Bratic (acting)	496-6793		
Asst. Dir.—Dr. Gio Gori (acting)	496-6616		
Asst. Dir.—Dr. John B. Moloney (acting)	496-1038		
Asst. Dir.—Dr. Bayard H. Morrison III	496-3308		
Asst. Dir.—Dr. Richard A. Tjalma	496-5854		
Laboratory Animal Science Dir.—Dr. A.E. New	496-1866		
Scientific Coordinator for Frederick Cancer Research Center—Dr. William W. Payne	393-1839		
FCRC Administrative Officer—Richard Carter	393-1839		
Office of Research Safety Dir.— Dr. W. Emmett Barkley	496-1862		
Journal of NCI Editor in Chief— Dr. John C. Bailar III	427-8620		
<b>DIV. OF CANCER BIOLOGY &amp; DIAGNOSIS</b>			
Director—Dr. Alan S. Rabson	496-4345		
Central Animal Facility Head—William Hinkle	496-1535		
Administrative Officer—Larry Willhite (acting)	496-3381		
Planning and Analysis Branch			
Chief—Dr. Ihor Masnyk	496-3251		
Laboratory of Biochemistry			
Chief—Dr. Robert Goldberger (until he leaves for his new position with NIH)	496-5937		
Protein Chemistry Section Chief— Dr. Elbert Peterson	496-1208		
Biosynthesis Section Chief—Dr. Edward Kuff	496-6855		
Cellular Regulation Section Chief— Dr. Robert Goldberger	496-5957		
Nucleic Acid Enzymology Section Chief— Dr. Maxine Singer	496-1581		
Biochemistry of Gene Expression Section Chief— Dr. E.B. Thompson	496-4561		
Developmental Biochemistry Section Chief— Dr. Igor Dawid	496-9616		
Laboratory of Molecular Biology			
Chief—Dr. Ira H. Pastan	496-4797		
Biochemical Genetics Section Chief— Dr. Max Gottesman	496-4894		
Cell Organization Section Chief— Dr. Seymour Wollman	496-2240		
Gene Regulation Section Chief— Dr. Benoit De Crombrughe	496-1018		
Laboratory of Pathophysiology			
Chief—Dr. Pietro M. Gullino	496-1557		
Cell Cycle Regulation Section Chief— Dr. William Kidwell	496-1258		
Cellular and Molecular Physiology Section Chief— Dr. Herbert Cooper	496-2886		
Membrane Biology Section Chief— Dr. Pedro Pinto Da Silva	496-1550		
Energy Metabolism Section Chief— Dr. Seoras Morrison	496-3651		
Nucleic Acids Section Chief— Dr. Walter Schneider	496-3625		
Radiation Biology Section Chief— Dr. Peter Riesz	496-4036		
Laboratory of Theoretical Biology			
Chief—Dr. Mones Berman (acting)	496-4781		
Dermatology Branch			
Chief—Dr. Stephen Katz (acting)	496-2481		
Metabolism Branch			
Chief—Dr. Thomas W. Waldman	496-6653		
Immunophysiology Section Chief— Dr. Warren Strober	496-5387		
Cellular Immunology Section Chief— Dr. Robert Blaese	496-5396		
Endocrinology Section Chief—Dr. James Phang	496-3097		
Laboratory of Pathology			
Chief—Dr. Alan S. Rabson (acting)	496-3185		
Surgical Pathology & Postmortem Section Chief— Dr. Jose Costa	496-3325		
Cytopathology Section Chief— Dr. Elizabeth W. Chu	496-6355		
Ultrastructural Pathology Section Chief— Dr. Timothy Triche	496-3185		
Hematopathology Section Chief— Dr. Costan W. Berard	496-1567		
Viral Oncology & Molecular Pathology Section Chief—Dr. Peter Howley	496-2176		
Comparative Oncology Section Chief— Dr. Clyde J. Dawe	496-4970		
Pathology Technology Section Chief— Barbara Coolidge	496-5951		
Quantitative Cytology Section Chief— Stuart Bentley (acting)	496-5282		
Image Processing—Dr. Lewis Lipkin	496-2394		
<b>DCBD Extramural Research Program</b>			
Associate Director for Extramural Research— Dr. Ihor Masnyk	496-3251		
Breast Cancer Program Coordinating Branch			
Chief—Dr. D. Jane Taylor	496-6718		
Epidemiology Projects Section Chief— Dr. Elizabeth Anderson	496-6718		
Diagnostic Projects Section Chief— Dr. Bernice Radovich	496-6773		
Therapeutic Projects Section Chief— Dr. Mary Sears	496-6718		
Experimental Biology Section Chief— Chester Piczak	496-6718		
Information Section Chief—Dr. James Reid	496-6773		
Diagnosis Branch			
Chief—Dr. K. Robert McIntire	496-1591		
General Diagnosis Section Chief—McIntire			
Diagnostic Radiology Section Chief— Dr. R. Quentin Blackwell	496-1591		
Cytology Automation Section Chief— Dr. Bill Bunnag	496-1591		
Cancer Biology Branch			
Chief—Dr. Brian Kimes (acting)	496-7028		
Tumor Biology Section Chief—Kimes			
Cellular Immunology, Clinical Immunology, Molecular Immunology Sections—Chief Dr. David Kizskiss (for all three)	496-7815		
<b>Immunology Program (intramural)</b>			
Director—Dr. William Terry	496-5461		
Macromolecular Biology—Peter T. Mora	496-6538		
Immunology Branch			
Chief—Terry			
Immunotherapy Section Chief— Dr. Richard Hodes	496-1376		
Transplantation Biology Section Chief— Dr. David Sachs	496-1085		
Laboratory of Cell Biology			
Chief—Dr. Lloyd W. Law	496-3363		
Immunochemistry Section Chief— Dr. Michael Potter	496-2777		
Ultrastructural Biology Section Chief— Dr. Nelson A. Wivel	496-2744		
Viral Oncogenesis Section Chief— Dr. Kenneth S. Chang (acting)	496-5710		
Laboratory of Immunodiagnosis			
Chief—Dr. Ronald Herberman	496-1366		
Laboratory of Immunobiology			
Chief—Dr. Herbert J. Rapp	496-6208		
Assoc. Chief—Dr. Tibor Borsos	496-3428		

Cellular Immunity Section Chief—Rapp (acting)  
 Humoral Immunity Section Chief—Borsos  
 Immunopathology Section Chief—  
 Dr. Edward J. Leonard 496-3428

**DIV. OF CANCER CAUSE & PREVENTION**

Director—Dr. Gregory T. O'Connor 496-6618  
 Special Asst. Dir.—Dr. Louis Sibal 496-5946  
 Scientific Coordinator for Environmental Cancer—  
 Dr. Herman F. Kraybill 496-1625  
 Asst. Dir. for Extramural Activities—  
 Dr. John Cooper 496-1882  
 Asst. to the Director—Dr. James Sontag 496-5108  
 International Cancer Research Data Bank Dir.—  
 Dr. John H. Schneider 427-8759  
 Administrative Officer—John M. Miller 496-6556  
 Administrative Officer for Extramural Program—  
 Joan Topalian 496-4241  
 Administrative Officer for Intramural Program—  
 Robert Velthuis Jr. 496-6271  
 Biological Carcinogenesis Branch (Extramural)  
 Chief—Dr. James T. Duff 496-9448  
 Chemical and Physical Carcinogenesis Branch  
 (Extramural) Chief—Dr. Thaddeus Domanski 496-4141

**Carcinogenesis Research Program**

Assoc. Dir. for Carcinogenesis Research (vacant)  
 Laboratory of Biology  
 Chief—Dr. Joseph Di Paolo 496-6441  
 Somatic Cell Genetics Section Chief—DiPaolo  
 Tumor Biology Section Chief—  
 Charles Evans 496-6441  
 Laboratory of Molecular Carcinogenesis  
 Chief—Dr. Harry V. Gelboin 496-6849  
 Cell Genetics Section Chief—  
 Dr. Takeo Kakunaga 496-1350  
 Nucleic Acids Section Chief—  
 Dr. Tsuyoshi Kakefuda (acting) 496-5004  
 Protein Section Chief—  
 Dr. Andrew C. Peacock 496-5880  
 Metabolic Control Section Chief—Gelboin (acting—  
 Laboratory of Experimental Pathology  
 Chief—Dr. Umberto Saffiotti 496-2048  
 In Vitro Pathogenesis Section Chief—  
 Dr. Stuart H. Yuspa 496-2162  
 Perinatal Carcinogenesis Section Chief—  
 Dr. Jerry M. Rice 496-2099  
 Human Tissue Studies Section Chief—  
 Dr. Curtis C. Harris 496-2090  
 Differentiation Control Section Chief—  
 Dr. Luigi De Luca 496-2698  
 Laboratory of Carcinogen Metabolism  
 Chief—Dr. Elizabeth Weisburger 496-5688  
 Analytical Chemistry Section Chief—  
 Dr. Larry K. Keefer 496-1323  
 Nutrition and Metabolism Section Chief—  
 Dr. Lionel A. Poirier 496-9263  
 Laboratory of Chemoprevention  
 Chief—Dr. Michael B. Sporn 496-5391

**Field Studies & Statistics Program**

Associate Director (vacant)  
 Administrative Officer—Colleen Sherwood 496-1282  
 Biometry Branch  
 Chief—Dr. Earl F. Pollack 496-1843  
 Computer Science Section—Theodore Weiss 496-1606  
 Clinical & Diagnostic Trials Section Chief—  
 Dr. David P. Byar 496-4208  
 Demographic Analysis Section Chief—  
 Dr. John L. Young Jr. 496-5251  
 Biometric Research & Analytic Studies Section  
 Chief—Dr. Max H. Myers 496-6365

Mathematical Statistics & Applied Mathematics  
 Section Chief—Dr. John J. Gart 496-3234  
 Clinical Epidemiology Branch  
 Chief—Dr. Joseph F. Fraumeni Jr. 496-1691  
 Environmental Studies Section Chief—  
 Dr. Robert N. Hoover 496-1691  
 Analytical Studies Section Chief—  
 Dr. William Blot 496-4153  
 Occupational Studies Section Chief—  
 Fraumeni (acting)  
 Population Studies Section Chief—  
 Dr. Thomas Mason 496-4375  
 Radiation Studies Section—  
 Charles Land, John Boice 496-1691

**Viral Oncology Program**

Assoc. Dir. for Viral Oncology—  
 Dr. Louis R. Sibal (acting) 496-5946  
 Administrative Officer—Robert Velthuis Jr. 496-6271  
 Scientific Coordinator, Viral Oncology Program,  
 FCRC—Dr. Henry J. Hearn 393-1839  
 Laboratory of Molecular Virology  
 Chief—Dr. Robert A. Manaker 496-3323  
 Microbiology Section Chief—  
 Dr. Berge Hampar 496-3323  
 Cell Physiology Section Chief—vacant  
 Virus Tumor Biochemistry Section Chief—  
 Dr. George Vande Woude 496-6738  
 Laboratory of Tumor Virus Genetics  
 Chief—Dr. Edward Scolnick 496-9365  
 Molecular Virology Section Chief—Scolnick  
 Viral Biochemistry Section Chief—  
 Dr. Robert Bassin 496-9512  
 Cellular Transformation Section Chief—  
 Dr. John Bader 496-2138  
 Carcinogenesis Regulation Section, Viral Immuno-  
 genetics Section—Scolnick acting chief for both  
 Laboratory of Cellular & Molecular Biology  
 Chief—Dr. Stuart Aaronson 496-6462  
 Animal Virology & Field Studies Section Chief—  
 Dr. Padman Sarma 496-9464  
 Molecular Biology Section Chief—Aaronson  
 Biohazards Research Section Chief—  
 Dr. Arnold Fowler 393-1839  
 Viral Genetics Section Chief—  
 Dr. John Stephenson (acting) 393-1839  
 Viral Immunology Section Chief—  
 Dr. Robert Huebner 496-3301  
 Viral Immunotherapy Section Chief—vacant  
 In Vitro Carcinogenesis Section Chief—  
 Dr. Katherine S. Mifflin 496-2617  
 Laboratory of Viral Carcinogenesis  
 Chief—Dr. George Todaro 496-6135  
 Cell Biology Section Chief—  
 Dr. Charles Boone 496-5141  
 Immunology Section Chief—vacant  
 Viral Leukemia & Lymphoma Section Chief—  
 Todaro 703-256-0086  
 Viral Control Section Chief—  
 Dr. Peter Fischinger 496-6588  
 Ultrastructural Studies Section Chief—  
 Dr. Ursula Heine 496-4311  
 Tumor Virus Detection Section Chief—  
 Dr. Jeffrey Schlom 703-256-0086  
 Viral Pathology Section Chief—  
 Dr. Charles J. Sherr 496-6135  
 Clinical Studies Section Chief—  
 Dr. Paul Levine 496-1975

**DIV. OF CANCER CONTROL & REHABILITATION**  
 Director—Dr. William Terry (acting) 427-8640

Special Assistant to the Director—  
 Dr. Vincent Groupe 427-8652  
 Special Assistant for Liaison—  
 Dr. Margaret H. Sloan 427-8633  
 Administrative Officer—Hugh E. Mahanes Jr. 427-8644  
 Writer-Editor—Cheryl Bleiberg 427-8644  
 Office of Planning & Analysis  
 Chief—H. Clifford Noyes (acting) 427-8636  
 Program Director for Educational Resources—  
 Dr. Arlene R. Barro 427-8636  
 Program Analyst—Linda M. Bremerman 427-8636  
 Executive Secretary—  
 Dr. Robert G. Burnight 427-8630  
 Biostatistician—Dr. Gary Cutter 427-8630  
 Program Director for Statistical & Evaluation  
 Projects—Dr. David Monsees 427-8630  
 Program Director for Communications Resources  
 & Development—Adel Nusbaum 427-8636  
 Community Special Projects Branch  
 Chief—Dr. Veronica L. Conley 427-8669  
 Program Analyst—Mary Asdell 427-8666  
 Program Director for Medical Oncology—Community  
 Activities—Dr. Donald N. Buell 427-8664  
 Program Director for Centers Outreach—  
 Dr. Carlos E. Caban 427-8669  
 Special Assistant—Dr. Margaret Holmes 427-8669  
 Asst. Program Director for Community Based Cancer  
 Control Projects—Dr. J. Yvonne Webb 427-8666  
 Treatment, Rehabilitation & Continuing Care Branch  
 Chief—Janet L. Lunceford (acting) 427-8656  
 Program Analyst—Carol Barrett 427-8656  
 Program Director for Clinical Cooperative  
 Groups—Dr. Harry Handelsman 427-8656  
 Program Director for Social Science Projects—  
 Dr. Rosemary Yancik 427-8656  
 Program Director for Rehabilitation—  
 Lawrence D. Burke 427-8656  
 Health Science Administrator—  
 Dr. Sandra M. Levy 427-8656  
 Asst. Program Director for Rehabilitation-IPA  
 Dr. Mary Ann Sestili 427-8656  
 Preventive Medicine Branch  
 Chief—Dr. Richard D. Costlow 427-8648  
 Program Analyst—Victoria G. Goforth 427-8648  
 Program Director for Pathology—  
 Dr. Chauncey G. Bly 427-8648  
 Program Director for Gynecologic Cancer—  
 Dr. Robert T. Bowser 427-8648  
 Program Director for Radiology—  
 Dr. Dorothy R. Brodie 427-8648  
 Program Director for Carcinogenesis—  
 Dr. Andrew F. Hegyeli 427-8652  
 Asst. Project Director for Breast Cancer Detection  
 Demonstration Projects—  
 Dr. John E. Lane 427-8648  
 Program Director for Radiation Prevention—  
 Dr. Winfred T. Malone 427-8652

#### DIV. OF CANCER RESEARCH RESOURCES & CENTERS

(This division will be renamed the Div. of Extramural Activities when the reorganization has been completed. The organ site, research and clinical manpower branches will be moved to other divisions)

Director—Dr. Thomas J. King 496-5147  
 Deputy Director—Dr. William A. Walter 496-4218  
 Special Asst. Director—Dr. Samuel Price (acting) 496-9138  
 Special Asst. to Director—Dr. Mary A. Fink 496-7173  
 Administrative Officer—Edith F. Phillips 496-5915  
 Committee Management Officer—  
 Marjorie F. Early 496-5708

Research Analysis & Evaluation Branch  
 Chief—Harry Y. Canter 496-7391  
 Scientific Analysis—Rosemary M. Cuddy 496-7391  
 Grants Administration Branch  
 Chief—Leo F. Buscher Jr. 496-7753  
 Basic Research Team Leader—  
 Robert E. Hawkins Jr. 496-7444  
 Resource Support Team Leader—  
 Adele M. Leff 496-7233  
 Clinical Research Team Leader—  
 Ethel M. Rogoff 496-7233  
 Grants Processing Section—Clara Wolfe 496-7987  
 Grants Financial Data & Analysis Branch  
 Chief—Robert E. Spallone 496-7756  
 Review and Referral Branch  
 Chief—Dr. David L. Jofte 496-7903  
 Cancer Control Grant Review Committee—  
 Dr. Robert F. Browning 496-7413  
 Tumor Immunology Review Committee—  
 Dr. Clarice E. Gaylord 496-7628  
 Clinical Trials Review Committee—  
 Dr. Gerald U. Liddel 496-7575  
 Developmental Therapeutics Review Committee—  
 Liddel  
 Cancer Center Support Review Committee—  
 Dr. Robert Manning 496-7721  
 Cancer Control Intervention Programs Review  
 Committee—Dr. Louis M. Ouellette 496-7413  
 Cancer Special Program Advisory Committee—  
 Dr. William R. Sanslone 496-7565  
 Clinical Cancer Program Project Review  
 Committee—Dr. Dorothy MacFarlane 496-7481  
 Biometry and Epidemiology Review Committee—  
 Dr. Wilna A. Woods 496-7153  
 Cause & Prevention Scientific Review Committee—  
 Dr. Eugene Zimmerman 496-7575  
 Special Review Committee—  
 Dr. O.M. Meredith 496-7903  
 Ad Hoc Construction Review Committee—  
 Hernon Fox 496-7575  
 Organ Site Programs Branch  
 Chief—Dr. Samuel Price 496-7194  
 Bladder Program Director—Dr. William E.  
 Dr. William E. Straile 496-7194  
 Large Bowel Program Director—  
 Dr. Vincent Chairoli 496-7194  
 Prostate Program Director—  
 Dr. Andrew Chiarodo 496-7194  
 Pancreas Program Director—Straile  
 Research Manpower Branch  
 Chief—Dr. Barney C. Lepovetsky 496-7803  
 Individual Fellowships Section Chief—  
 Dr. Jean Sipe 496-7865  
 Institutional Fellowships Section Chief—  
 Lepovetsky  
 Evaluation & Review—Dr. Leon J. Niemiec 496-7803  
 Clinical Manpower Branch  
 Chief—Dr. Margaret H. Edwards 496-7761

(Listings for Div. of Cancer Treatment and Carcinogenesis Testing Program staff members will appear next week in *The Cancer Letter*.)

#### NCI CONTRACT AWARDS

**Title:** Psychological aspects of breast cancer, four month extensions  
**Contractors:** West Coast Cancer Foundation, San Francisco, \$2,180; and Midwest Research Institute, Kansas City, Mo., \$48,838.

**Title:** Radiologic physics centers, one-year renewal  
**Contractor:** American Assn. of Physicists in Medicine, Chicago, \$206,260.

**Title:** Synthesis of polycyclic aromatic hydrocarbon derivatives, continuation  
**Contractor:** Midwest Research Institute, \$542,000.

### RFPs AVAILABLE

*Requests for proposal described here pertain to contracts planned for award by the National Cancer Institute, unless otherwise noted. Write to the Contracting Officer or Contract Specialist for copies of the RFP, citing the RFP number. Some listings will show the phone number of the Contract Specialist, who will respond to questions. Listings identify the respective sections of the Research Contracts Branch which are issuing the RFPs. Address requests to the contract officer or specialist named, NCI Research Contracts Branch, the appropriate section, as follows:*

*Biology & Diagnosis Section and Biological Carcinogenesis & Field Studies Section—Landow Building, Bethesda, Md. 20205; Control & Rehabilitation Section, Chemical & Physical Carcinogenesis Section, Treatment Section, Office of the Director Section—Blair Building, Silver Spring, Md. 20910. Deadline date shown for each listing is the final day for receipt of the completed proposal unless otherwise indicated.*

#### RFP N01-CO-05473-10

**Title:** *Cancer Information Clearinghouse and allied services (100% set-aside for small business concerns)*

**Deadline:** *Oct. 22*

The Office of Director, NCI, is seeking an organization within the Washington D.C. metropolitan area which will operate and provide technical support services for the Cancer Information Clearinghouse. These shall include the performance of tasks that involve acquiring information, cataloging and indexing, operating storage and retrieval systems, and supporting dissemination of bibliographic forms of public information and educational products. Officers shall be limited to those firms having operating facilities within 35 miles of the NIH campus, as continued interaction between the contractor and the NCI project officer is often necessary.

**Contract Specialist:** Linda Waring  
Office of Director Section  
301-427-8747

### SOURCES SOUGHT

**Project No.** N01-CP-FS-01004-77

**Title:** *Multifaceted in vitro study of the genetic and cellular biology of cells from patients at high risk of cancer*

**Deadline (for resumes):** *Sept. 24*  
NCI's Clinical Epidemiology Branch knows of only

one organization capable of a comprehensive in vitro investigation of fibroblast, blood cultures, and other cell lines obtained by the branch during clinical investigations of persons at high risk of cancer because of peculiarities in their personal, environmental, or family history. That organization is the Institute for Medical Research in Camden, N.J.

Well established biomedical research organizations are invited to submit qualifications for review. The project involves collaboration with investigators of the Clinical Epidemiology Branch to design and accomplish an extensive look at cells from selected individuals. Minimal required activities are:

1. Facilitate and culture of transport biopsy and blood specimens to assure maximum viability;
2. Screen specimens for microbial and cellular contamination, log in, and bank safely;
3. Execute a simultaneous battery of assays on similar passage cells: banded karyotype, sister chromatid exchange, in vitro mutagenesis assay, in vitro viral transformation assay, and in vitro assay for DNA repair and cell sensitivity to radiation and radiomimetic agents; together with the Clinical Epidemiology Branch, interpret results and correlate with clinical manifestations;
- and 4. Distribute specimens to additional investigators as requested.

Minimal acceptable qualifications are: 1. an institution within 150 miles of NIH Bethesda; 2. available intramural staff with experience in each assay mentioned in item 3 above, as documented by publication in the biomedical literature of research findings using such assays; 3. proven experience and expertise in tissue culture techniques and cell banking and distribution; 4. intramural computer support staff to consult and aid in data management; and 5. all facilities to perform all assays in one geographic location (under one roof).

This is not a request for proposal. Responses should not include cost or pricing information. Concise responses—a maximum of 10 pages—to the points mentioned above are requested. Qualifications of scientists and technical personnel and description of facilities and bibliography to document qualification item number 2 are required. Five copies of the statement must be submitted. The Institute will evaluate all responses. Unqualified organizations will be notified. The government reserves the right not to accept offers limited to a subsection, small elements or portions of the overall work.

**Contracting Officer:** Sydney Jones  
Viral Oncology & Field  
Studies  
301-496-1781

### The Cancer Letter \_ Editor Jerry D. Boyd

Published fifty times a year by The Cancer Letter, Inc., P.O. Box 2370, Reston, Virginia 22090. Also publisher of The Clinical Cancer Letter. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.